📊 DYN Key Takeaways
Is Dyne Therapeutics, Inc. (DYN) a Good Investment?
Dyne Therapeutics is a pre-revenue biopharmaceutical company with severe cash burn, burning through $403.2M in operating cash flow annually against a $893.4M cash position, implying a runway of approximately 2.2 years at current burn rates. The company is unprofitable with negative operating income of -$468.2M and negative ROE/ROA, indicating it is not yet generating commercial revenue and faces significant execution risk in bringing pipeline candidates to market. While the strong balance sheet and minimal debt provide near-term financial stability, the fundamental business model is unproven and the cash burn trajectory necessitates successful clinical progression and eventual commercialization.
Dyne Therapeutics shows the classic profile of a development-stage biotech: no commercial revenue, deep operating losses, and heavy negative free cash flow, but an unusually strong cash position and very low leverage. Fundamentally, the balance sheet provides meaningful runway to fund R&D, yet the business still depends on future clinical and regulatory execution before its financial model can improve materially.
Why Buy Dyne Therapeutics, Inc. Stock? DYN Key Strengths
- Strong cash position of $893.4M provides 2+ years of runway at current burn rates
- Low leverage with debt-to-equity ratio of 0.15x limits financial distress risk
- Exceptional liquidity with current ratio of 22.25x ensures near-term ability to fund operations
- Moderate insider activity suggests continued management engagement
- Very strong liquidity with $893.37M in cash and a 22.25x current ratio
- Low balance-sheet leverage with debt/equity of 0.15x and equity of $972.13M
- Large asset base relative to liabilities, giving the company flexibility to fund ongoing development
DYN Stock Risks: Dyne Therapeutics, Inc. Investment Risks
- Pre-revenue stage with no commercial product generating sales; entirely dependent on pipeline success
- Severe cash burn of $403.2M annually in operating activities with free cash flow of -$405.1M creates existential funding timeline pressure
- Negative profitability metrics across all dimensions (operating income -$468.2M, ROE -45.9%, ROA -37.6%) with no clear path to positive returns in near term
- Clinical development risk inherent to biopharmaceuticals; any trial failures or regulatory setbacks could accelerate cash depletion
- Will require significant capital raises or partnership deals to extend runway beyond 2-3 years
- No revenue base or gross profit, so profitability depends entirely on future commercialization success
- High cash burn with -$403.21M operating cash flow and -$405.13M free cash flow
- Deep losses and negative returns on equity/assets indicate weak current operating economics
Key Metrics to Watch
- Quarterly operating cash burn rate and cash runway extension
- Clinical trial progression and regulatory milestone achievements for pipeline candidates
- Quarterly cash position and any capital raise activities or strategic partnerships
- Year-over-year comparison of operating expenses and R&D spending efficiency
- Quarterly operating cash burn and remaining cash runway
- Any transition from pre-revenue status toward sustainable product revenue or major milestone income
Dyne Therapeutics, Inc. (DYN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 22.25x current ratio provides a solid financial cushion.
DYN Profit Margin, ROE & Profitability Analysis
DYN vs Healthcare Sector: How Dyne Therapeutics, Inc. Compares
How Dyne Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Dyne Therapeutics, Inc. Stock Overvalued? DYN Valuation Analysis 2026
Based on fundamental analysis, Dyne Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Dyne Therapeutics, Inc. Balance Sheet: DYN Debt, Cash & Liquidity
DYN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Dyne Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.95 indicates the company is currently unprofitable.
DYN Revenue Growth, EPS Growth & YoY Performance
Dyne Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
DYN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Dyne Therapeutics, Inc. (CIK: 0001818794)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DYN
What is the AI rating for DYN?
Dyne Therapeutics, Inc. (DYN) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DYN's key strengths?
Claude: Strong cash position of $893.4M provides 2+ years of runway at current burn rates. Low leverage with debt-to-equity ratio of 0.15x limits financial distress risk. ChatGPT: Very strong liquidity with $893.37M in cash and a 22.25x current ratio. Low balance-sheet leverage with debt/equity of 0.15x and equity of $972.13M.
What are the risks of investing in DYN?
Claude: Pre-revenue stage with no commercial product generating sales; entirely dependent on pipeline success. Severe cash burn of $403.2M annually in operating activities with free cash flow of -$405.1M creates existential funding timeline pressure. ChatGPT: No revenue base or gross profit, so profitability depends entirely on future commercialization success. High cash burn with -$403.21M operating cash flow and -$405.13M free cash flow.
What is DYN's revenue and growth?
Dyne Therapeutics, Inc. reported revenue of N/A.
Does DYN pay dividends?
Dyne Therapeutics, Inc. does not currently pay dividends.
Where can I find DYN SEC filings?
Official SEC filings for Dyne Therapeutics, Inc. (CIK: 0001818794) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DYN's EPS?
Dyne Therapeutics, Inc. has a diluted EPS of $-3.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DYN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Dyne Therapeutics, Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DYN stock overvalued or undervalued?
Valuation metrics for DYN: ROE of -45.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DYN stock in 2026?
Our dual AI analysis gives Dyne Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DYN's free cash flow?
Dyne Therapeutics, Inc.'s operating cash flow is $-403.2M, with capital expenditures of $1.9M.
How does DYN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -45.9% (avg: 15%), current ratio 22.25 (avg: 2).